{
    "clinical_study": {
        "@rank": "151435", 
        "acronym": "ATTR-ACT", 
        "arm_group": [
            {
                "arm_group_label": "Tafamidis - 20 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Tafamidis - 80 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will investigate the efficacy, safety, and tolerability of an oral dose of 20 mg\n      or 80 mg tafamidis meglumine soft gel capsules in comparison to placebo and given once\n      daily, in addition to standard of care, for 30 months in subjects diagnosed with\n      transthyretin cardiomyopathy (familial and wild-type).  The study is designed to assess the\n      potential for benefit from treatment with tafamidis relative to placebo based on all-cause\n      mortality and frequency of cardiovascular-related hospitalizations."
        }, 
        "brief_title": "Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Transthyretin (TTR) Amyloid Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Amyloidosis", 
                "Cardiomyopathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or\n             clinical evidence of HF (without hospitalization) manifested by signs or symptoms of\n             volume overload or elevated intracardiac pressures (e.g., elevated jugular venous\n             pressure, shortness of breath or signs of pulmonary congestion on x-ray or\n             auscultation, peripheral edema) that required/requires treatment with a diuretic for\n             improvement,\n\n          -  Evidence of cardiac involvement by echocardiography with an end-diastolic\n             interventricular septal wall thickness > 12 mm,\n\n          -  Presence of amyloid deposits in biopsy tissue and presence of a variant TTR genotype\n             and/or TTR precursor protein identification by mass spectrometry.\n\n        Exclusion Criteria:\n\n          -  A New York Heart Association (NYHA) classification of IV.\n\n          -  Presence of primary (light chain) or secondary (SAA) amyloidosis.\n\n          -  Prior liver or heart transplantation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994889", 
            "org_study_id": "B3461028"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tafamidis - 20 mg", 
                "description": "Tafamidis 20 mg in soft gel capsules administered once a day for 30 months", 
                "intervention_name": "Tafamidis", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tafamidis - 80 mg", 
                "description": "Tafamidis 80 mg in soft gel capsules administered once a day for 30 months", 
                "intervention_name": "Tafamidis", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo in soft gel capsules administered once a day for 30 months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "amyloidosis", 
            "amyloid"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461028&StudyName=Safety%20and%20Efficacy%20of%20Tafamidis%20in%20Patients%20with%20Transthyretin%20Cardiomyopathy"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85054"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oak Lawn", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60453"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70121"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10034"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A hierarchical combination of the endpoints for a pooled analysis of the tafamidis treatment groups in comparison to placebo", 
            "measure": "All-cause mortality and frequency of cardiovascular-related hospitalization", 
            "safety_issue": "Yes", 
            "time_frame": "From Baseline to Month 30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994889"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from Baseline to Month 30 in the total distance walked in 6 minutes.", 
                "measure": "6-Minute Walk Test (6MWT).", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Month 30"
            }, 
            {
                "description": "Change from Baseline to Month 30 in the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS).", 
                "measure": "Kansas City Cardiomyopathy Questionnaire (KCCQ)", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Month 30"
            }, 
            {
                "description": "The total number of deaths adjudicated as being related to cardiovascular causes.", 
                "measure": "Cardiovascular-related mortality", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to Month 30"
            }, 
            {
                "description": "The number of times that a subject is hospitalized for cardiovascular-related causes.", 
                "measure": "Frequency of cardiovascular-related hospitalization", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to Month 30"
            }, 
            {
                "description": "The total number of deaths in the study.", 
                "measure": "All-cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to Month 30"
            }, 
            {
                "description": "Tafamidis stabilizes the transthyretin (TTR) tetramer by binding with very high affinity to the two thyroxine binding sites, preventing the tetramer from dissociating along the weak dimer-dimer interface.  TTR stabilization is a measure of the degree of stabilization afforded the TTR molecule by tafamidis, expressed as a percentage change from baseline.", 
                "measure": "TTR stabilization at Month 1", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Month 1"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}